Related Experiment Video
Updated: May 19, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Somatostatin receptor expression in non-medullary thyroid carcinomas
Kalliopi Pazaitou-Panayiotou1, Eva Tiensuu Janson, Triantafyllia Koletsa
1Department of Endocrinology, Endocrine Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.
Hormones (Athens, Greece)
|August 22, 2012
Summary
Non-medullary thyroid cancers frequently express somatostatin receptor (SSTR) subtypes, suggesting peptide receptor radionuclide therapy (PRRT) could be a viable treatment option for advanced disease.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Peptide receptor radionuclide therapy (PRRT) relies on radiolabeled peptides binding to target receptors.
- Understanding somatostatin receptor (SSTR) expression is crucial for evaluating PRRT efficacy.
Purpose of the Study:
- To characterize SSTR subtype expression in non-medullary thyroid carcinomas.
- To assess the potential of PRRT for treating progressive or metastatic non-medullary thyroid cancer.
Main Methods:
- Tissue microarrays were created from 47 non-medullary thyroid carcinoma samples.
- Immunohistochemical staining was performed using five SSTR subtype-specific antibodies.
Main Results:
- All non-medullary thyroid carcinomas expressed SSTR subtypes sst2 and sst3.
- SSTR subtypes sst1 and sst5 were found in 75% of cases, and sst4 in 38%.
- Over three SSTR subtypes were coexpressed in 36 out of 47 cases, with low/absent expression in normal thyroid tissue.
Conclusions:
- Non-medullary thyroid carcinomas exhibit widespread expression of all SSTR subtypes.
- This finding supports further investigation into PRRT for iodine-131 refractory metastatic non-medullary thyroid carcinomas.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...